In this issue of Blood, Gagelmann et al1 describe an integrated clinical-molecular prognostic model (Myelofibrosis Transplant Scoring System [MTSS]) to predict outcome post stem cell transplant (SCT) in myelofibrosis (MF). MF is a clonal stem cell neoplasm with heterogeneous clinical phenotypes and well-defined driver mutations found in ∼90% of the cases.2 Despite the introduction of JAK inhibitors,3 MF still remains an incurable disease with a median survival of 4 to 5 years. SCT is an option for MF patients,4 but, because of the very high risk of mortality, the patient selection is very critical.
Stem cell transplant in MF: It’s time to personalize / F. Passamonti. - In: BLOOD. - ISSN 0006-4971. - 133:20(2019), pp. 2118-2120. [10.1182/blood-2019-03-900860]
Stem cell transplant in MF: It’s time to personalize
F. Passamonti
Primo
2019
Abstract
In this issue of Blood, Gagelmann et al1 describe an integrated clinical-molecular prognostic model (Myelofibrosis Transplant Scoring System [MTSS]) to predict outcome post stem cell transplant (SCT) in myelofibrosis (MF). MF is a clonal stem cell neoplasm with heterogeneous clinical phenotypes and well-defined driver mutations found in ∼90% of the cases.2 Despite the introduction of JAK inhibitors,3 MF still remains an incurable disease with a median survival of 4 to 5 years. SCT is an option for MF patients,4 but, because of the very high risk of mortality, the patient selection is very critical.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0006497120425509-main.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
233.61 kB
Formato
Adobe PDF
|
233.61 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.